You are here: Industry Insights > Theravance Biopharma

News List

Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903 pharmaceutical-business-review
June 30, 2020
Theravance Biopharma has dosed the first patient in the phase 2 study of lung-selective and nebulized Janus kinase inhibitor (JAKi) TD-0903 to treat hospitalised patients with acute lung injury (ALI) due to Covid-19.
First Subject Dosed in TD-0903 Study for Acute Lung Injury from COVID-19 americanpharmaceuticalreview
April 24, 2020
Theravance Biopharma announced the first healthy volunteer has been dosed in a Phase 1 study of TD-0903.
Theravance Responds to COVID-19 Pandemic contractpharma
April 14, 2020
Theravance Biopharma said that it is advancing TD-0903, a lung-selective nebulized Janus kinase inhibitor (JAKi) into clinical development.
Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program worldpharmanews
December 24, 2019
Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. and Pfizer Inc. announced that the companies have entered into a global license agreement for ...
Theravance Biopharma Announces First Patient Dosed in TD-1473 Study americanpharmaceuticalreview
December 27, 2018
Theravance Biopharma announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease. TD-1473 is a novel, potent, orally administered and ......
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease pharmafocusasia
November 26, 2018
Theravance Biopharma, Inc. announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease...